sr141716 has been researched along with Hyperglycemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degrace, P; Demizieux, L; Gresti, J; Muller, T; Troy-Fioramonti, S; Vergès, B | 1 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Henzen, C | 1 |
| Berry, C; Bourassa, MG | 1 |
2 review(s) available for sr141716 and Hyperglycemia
| Article | Year |
|---|---|
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
[Internal medicine--update 2006].
Topics: Adrenal Gland Neoplasms; Bradykinin; Carotid Stenosis; Clinical Trials as Topic; Contrast Media; Endarterectomy, Carotid; Esophageal and Gastric Varices; Female; Heart Failure; Humans; Hyperglycemia; Hypertension; Hyperthyroidism; Internal Medicine; Male; Middle Aged; Osteitis Deformans; Piperidines; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Renal Insufficiency; Rimonabant; Risk Factors; Stents; Stethoscopes; Weight Loss | 2007 |
2 other study(ies) available for sr141716 and Hyperglycemia
| Article | Year |
|---|---|
Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice.
Topics: Animals; Arachidonic Acids; Blood Glucose; Endocannabinoids; Gastrointestinal Motility; Gastrointestinal Transit; Hyperglycemia; Indoles; Male; Mice; Mice, Inbred C57BL; Piperidines; Polyunsaturated Alkamides; Postprandial Period; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant | 2015 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss | 2008 |